MED23 and lung adenocarcinoma: Indeed, we found that approximately 2.1% of lung adenocarcinoma patient samples in the TCGA database had mutations in MED23 utilizing relevant website analysis [29, 30] (Fig. S4A), and most of the mutations in MED23 led to a reduction in the copy number of MED23 (Fig. S4B, C).